I am a
Home I AM A Search Login

Papers of the Week


January 27, 2023


JAMA Dermatol


http://www.ncbi.nlm.nih.gov/pubmed/36630140?dopt=Abstract

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).

Authors

L Simpson E, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Lima R G, Witte MM, Xu W, ElMaraghy H, Natalie CR, Pierce E, Blauvelt A
JAMA Dermatol. 2023 Jan 11.
PMID: 36630140.

Abstract

Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy in a phase 2b trial, and two 52-week phase 3 trials.